These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 38638671)
1. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671 [TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Ringheim GE; Wampole M; Oberoi K Front Immunol; 2021; 12():662223. PubMed ID: 34803999 [TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776 [TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645 [TBL] [Abstract][Full Text] [Related]
6. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases. De Bondt M; Renders J; Struyf S; Hellings N Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213 [TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. Garg N; Padron EJ; Rammohan KW; Goodman CF J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294458 [TBL] [Abstract][Full Text] [Related]
8. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. Carnero Contentti E; Correale J Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195 [TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis. Shulga O; Chabanova A; Kotsiuba O Postep Psychiatr Neurol; 2023 Mar; 32(1):23-30. PubMed ID: 37287740 [TBL] [Abstract][Full Text] [Related]
10. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. Arneson LC; Carroll KJ; Ruderman EM Immunotargets Ther; 2021; 10():333-342. PubMed ID: 34485183 [TBL] [Abstract][Full Text] [Related]
11. Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. Robak E; Robak T J Clin Med; 2022 May; 11(10):. PubMed ID: 35628931 [TBL] [Abstract][Full Text] [Related]
12. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases. Lin P; Zhang D; Lin J Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005 [TBL] [Abstract][Full Text] [Related]
13. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy. García-Merino A Cells; 2021 Sep; 10(10):. PubMed ID: 34685540 [TBL] [Abstract][Full Text] [Related]
14. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review. Dybowski S; Torke S; Weber MS JAMA Neurol; 2023 Apr; 80(4):404-414. PubMed ID: 36780171 [TBL] [Abstract][Full Text] [Related]
17. Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus. Satterthwaite AB Front Immunol; 2017; 8():1986. PubMed ID: 29403475 [TBL] [Abstract][Full Text] [Related]
18. Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? Lorenzo-Vizcaya A; Fasano S; Isenberg DA Immunotargets Ther; 2020; 9():105-110. PubMed ID: 32582577 [TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis. Saberi D; Geladaris A; Dybowski S; Weber MS Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515 [TBL] [Abstract][Full Text] [Related]
20. Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib. De Bondt M; Renders J; de Prado PP; Berghmans N; Pörtner N; Vanbrabant L; de Oliveira VLS; Duran G; Baeten P; Broux B; Gouwy M; Matthys P; Hellings N; Struyf S J Leukoc Biol; 2024 Jul; ():. PubMed ID: 38976501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]